
    
      Participants will receive a single dose of intravenous (IV) BBP-631 and are monitored for 52
      weeks post-treatment. All participants who receive BBP-631 will be followed for an additional
      4 years for safety and efficacy in a separate long-term follow-up study. In total, all
      participants will be followed for at least 5 years after the date of treatment with BBP-631.
    
  